期刊文献+

HIF-1α基因沉默对裸鼠人肺癌移植瘤放射敏感性影响的观察 被引量:10

Effect of HIF-1α siliencing on human lung cancer xenografts radiosensitivity in nude mice
原文传递
导出
摘要 目的:探讨缺氧诱导因子-1α(HIF-1α)基因沉默对裸鼠肺癌移植瘤放射敏感性的影响。方法:采用A549和A549/HIF-1α(-)细胞株建立人肺癌移植瘤模型,分别给予5、10、15和20Gy单次剂量X射线照射,观察放射治疗对肿瘤的抑制作用,根据肿瘤生长延缓和照射剂量分析肿瘤剂量效应及HIF-1α基因沉默对在体肿瘤放射敏感性的影响。结果:放射治疗能明显抑制肿瘤生长,并观察到随照射剂量的增加肿瘤生长延缓愈显著,接受等剂量照射HIF-1α基因沉默肿瘤生长延缓更明显,根据肿瘤剂量效应曲线计算放射增敏比分别为1.40、1.34和1.31。结论:放射治疗能显著抑制A549和A549/HIF-1α(-)肿瘤生长,A549/HIF-1α(-)肿瘤对放射治疗更敏感。 OBJECTIVE: To observe the effect of HIF-1α siliencing on human lung cancer xenografts radiosensitivity in nude mice. METHODS: The human lung cancer model in nude mice were established with A549 and A549/HIF-1α(-) cell lines and were locally irradiated with single doses of 5,10,15 and 20 Gy radiation. The tumor inhibition by radiotherapy was observed. The tumor dose-response relationship and therapeutic gain of HIF-1α siliencing were analized by tumor growth delay and radiation dose. RESULTS: Radiotherapy could inhibit tumors growth apparently. The tumor growth delay was prolonged with radiation-dose increasing. It was longer in HIF-1α siliencing group than in A549 group irradiated by the same-dose X-ray. The sensitivity enhance ment ratio were 1. 40, 1. 34 and 1. 31. CONCLUSIONS: Both A549 and A549/HIF-1α(--) tumor growth can be inhibited by ra- diotherapy. The A549/HIF-1α-) xenografts are more sensitive to radiotherapy than A549 xenografts.
出处 《中华肿瘤防治杂志》 CAS 2011年第21期1665-1668,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(30570547) 山东省医药卫生科技发展计划(2009HZ078)
关键词 细胞低氧 肺肿瘤 辐射耐受性 基因沉默 小鼠 cell hypoxia lung neoplasms radiation tolerance gene silencing mice, nude
  • 相关文献

参考文献15

二级参考文献38

  • 1蒋祝昌,毕桂南,石胜良.高血压大鼠局灶性脑缺血再灌注后Survivin及Bcl-2表达[J].中国临床神经科学,2005,13(2):127-130. 被引量:6
  • 2谢晓冬,郑振东.分子靶点药物吉非替尼治疗复发难治性非小细胞肺癌的现状[J].中国实用内科杂志,2005,25(8):688-690. 被引量:9
  • 3王颖杰,王绿化,陈东福,周宗玫,欧广飞,梁军,张可,殷蔚伯.小细胞肺癌的三维适形放射治疗[J].中华肿瘤杂志,2005,27(9):570-572. 被引量:12
  • 4Liu-Bin Shi,Jian-Hua Huang,Bao-San Han.Hypoxia inducible factor-1α mediates protective effects of ischemic preconditioning on ECV-304 endothelial cells[J].World Journal of Gastroenterology,2007,13(16):2369-2373. 被引量:7
  • 5Salomon D S, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptor and tis ligands in primary non small cell lung cancers and adjacent benign lung[J]. Crit Rev Oncol Hematol, 1995,19(3), 183-232.
  • 6Rusch V, Bselga J, Cordon-Cardo C, er al. Differential expression of the epidermal growth factor receptor and tis ligands in primary non-small cell lung cancers and adjacent benigh lung[J]. Cancer Res,1993, 53(10 Suppl) :2379-2385.
  • 7Chang A, Parikh P, Thongprasert S, et al. Gefitinib in patients of Asian origin with refractory adbanced non-small cell lung cancer:subset analysis from the ISEL study[J]. Thorac Oncol, 2006, 1(8) :847-855.
  • 8Kris M G, Natale R B, Herbst R S, et al. A phase Ⅱ trial of um-and docetaxel based regimens(IDAEL2)[J]. Proc Am Soc Clin Oncol, 2002, 21:292a.
  • 9Curer T, Vrdoljak E, Gaafar R, et al. Phase Ⅱ , open label, randomaize study (SIGN) of single agent gefitinib(IRESSA) or docetaxel as second-line therapy in patients with advanced (stage [Ⅲbor Ⅳ ) non small cell lung cancer[J]. Anticancer Drugs, 2006,17(4):401- 109.
  • 10Quoix E, Breton J L, Ducolone A, et al. First line chemothera py with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase I1 study of 3 week versus 4-week schedule[J]. Lung Cancer, 2005, 47(3) :405- 412.

共引文献33

同被引文献128

引证文献10

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部